Frontiers in Cardiovascular Medicine. 2022 Feb 7
Yong Wu, Zhongxu Luo, Zhengtao Hu, Kun Lv, Yinhua Liu, and Deguo Wang
Products used in the paper Details Operation
AAV vector packaging AAV9-containing Ca(2+)/calmodulin-activated protein kinase II-a (CaMKIIa) prompter with or without -hChR2(H134R) (PackGene Biotech, 10^13 vg/ml) was drawn up into a 10 μl Hamilton syringe with a glass pipette and pulled to a 20μm tip (Hamilton, Shanghai, Ch). Then AAVs (3 μl) were injected into the dorsal horn (0.5mm depth) under control by a stereotaxic micromanipulator through previously reported methods Request Quote

Research Field: heart

Keywords: ischemia-reperfusion, ventricular arrhythmia, optogenetic, spinal cord, sympathetic nerve activity

AAV Serotype: AAV9

Dose: AAV9-containing Ca(2+)/calmodulin-activated protein kinase II-a (CaMKIIa) prompter with or without -hChR2(H134R) (PackGene Biotech, 10^13 vg/ml) was drawn up into a 10 μl Hamilton syringe a glass pipette and pulled to a 20μm tip (Hamilton, Shanghai, Ch). Then AAVs (3 μl) were injected into the dorsal horn (0.5mm depth) under control by a stereotaxic micromanipulator through previously reported methods

Routes of Administration: Then AAVs (3 μl) were injected into the dorsal horn (0.5mm depth) under control by a stereotaxic micromanipulator through previously reported methods

Targeted organ: heart

Animal or cell line strain: Adult male rats (Sprague Dawley)

Abstract

Background and ObjectivesSpinal cord stimulation can prevent myocardial ischemia and reperfusion arrhythmias, but the relevant neurons and mechanisms remain unknown. Thus, this study applied optogenetic techniques to selectively activate glutamatergic neurons at the thoracic spinal cord (T1 segment) for examining the anti-arrhythmia effects during acute myocardial ischemic-reperfusion.

Popular Services

AAV Packaging Service

AAV Analytical Service

Vector Design